CCP
ABBV icon

Corient Capital Partners’s AbbVie ABBV Stock Holding History

Corient Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$14.7M Hold
96,108
– – 1.1% 12
2022
Q2 		$14.7M Buy
96,108
+191
+0.2% +$29.2K 1.12% 12
2022
Q1 		$15.5M Buy
95,917
+6,576
+7% +$955K 1.03% 13
2021
Q4 		$12.1M Buy
89,341
+2,985
+3% +$353K 0.8% 19
2021
Q3 		$9.32M Sell
86,356
-3,200
-4% -$366K 0.68% 28
2021
Q2 		$10.1M Buy
89,556
+13,799
+18% +$1.55M 0.74% 22
2021
Q1 		$8.2M Buy
75,757
+1,961
+3% +$210K 0.7% 23
2020
Q4 		$7.91M Buy
73,796
+4,092
+6% +$393K 0.79% 25
2020
Q3 		$6.11M Buy
69,704
+1,130
+2% +$106K 0.7% 34
2020
Q2 		$6.73M Buy
68,574
+13,243
+24% +$1.17M 0.82% 24
2020
Q1 		$4.21M Buy
55,331
+13,187
+31% +$1.12M 0.66% 37
2019
Q4 		$3.73M Buy
42,144
+1,626
+4% +$135K 0.47% 50
2019
Q3 		$3.07M Buy
40,518
+833
+2% +$57.1K 0.43% 55
2019
Q2 		$2.88M Sell
39,685
-1,520
-4% -$119K 0.44% 50
2019
Q1 		$3.32M Sell
41,205
-10,616
-20% -$868K 0.54% 41
2018
Q4 		$4.78M Sell
51,821
-12,875
-20% -$1.13M 0.85% 18
2018
Q3 		$6.12M Hold
64,696
– – 1.02% 9
2018
Q2 		$5.99M Buy
64,696
+2,574
+4% +$251K 1.05% 8
2018
Q1 		$5.88M Sell
62,122
-16,551
-21% -$1.82M 1.08% 11
2017
Q4 		$7.61M Sell
78,673
-17,008
-18% -$1.6M 1.29% 6
2017
Q3 		$8.5M Sell
95,681
-8,436
-8% -$642K 1.61% 6
2017
Q2 		$7.55M Sell
104,117
-1,514
-1% -$102K 1.16% 11
2017
Q1 		$6.88M Buy
105,631
+21,349
+25% +$1.34M 1.07% 15
2016
Q4 		$5.28M Sell
84,282
-7,674
-8% -$468K 0.93% 16
2016
Q3 		$5.8M Buy
+91,956
New +$5.95M 1.07% 11

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Corient Capital Partners's ABBV Position: Q3 2022 in Review

Corient Capital Partners held its AbbVie (ABBV) position steady in Q3 2022 at 96,108 shares worth $14.7M. The position accounts for 1.1% of the portfolio, ranked #12.

Corient Capital Partners first reported a position in ABBV in Q3 2016 and has held it in 25 quarters since. The position peaked at $15.5M in Q1 2022. 2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

  • Corient Capital Partners held 96,108 shares of AbbVie worth $14.7M as of Q3 2022.
  • Corient Capital Partners left its AbbVie share count unchanged in Q3 2022.
  • AbbVie made up 1.1% of Corient Capital Partners's portfolio in Q3 2022, its #12 holding.
  • Corient Capital Partners first reported a position in AbbVie in Q3 2016 and has held it in 25 quarters since.
  • Corient Capital Partners's AbbVie position peaked at $15.5M in Q1 2022.
  • 2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.